Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Genentech announces topline results from Phase III trial of Avastin

Genentech announces topline results from Phase III trial of Avastin

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Gene research offers new hope for targeted breast cancer treatment

Gene research offers new hope for targeted breast cancer treatment

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Genta commences Phase 2 trial of tesetaxel on first subject

Genta commences Phase 2 trial of tesetaxel on first subject

Proteomics study reveals protein suppression makes cancers more susceptible to chemotherapy

Proteomics study reveals protein suppression makes cancers more susceptible to chemotherapy

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

Positive interim results of ARRY-380 in Phase 1 trial announced

Positive interim results of ARRY-380 in Phase 1 trial announced

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.